Quality

# New Three-year Business Plan, BEACON 2030 Phase II

## 3 Indicators and 6 Key Measures

Implement the reform of the profit structure and make investments in growth areas, and accelerate our transformation into a global MedTech company



| FY2026 Targets    |
|-------------------|
| ¥256.0 bil        |
| ¥157.0 bil        |
| ¥99.0 bil (38.7%) |
| 53%               |
| ¥38.5 bil (15%)   |
| ¥25.0 bil         |
| 12%               |
| 12%               |
|                   |

#### Growth

#### **Enhance product competitiveness**

- Focusing on strengthening our core Patient Monitoring Business, expanding Treatment Equipment Business including ventilators which are expected to grow rapidly, as well as Consumables and Services Business and Solutions Business including digital health solutions
- Focusing on strengthening technological capabilities and shortening the development time for new products

#### **Focus on growth of North America Business**

• Nihon Kohden will focus on its market strategy in three regions: Japan, North America, Rest of World [Japan] Strengthen customer base and achieve sustainable growth by enhancing customer value proposition [North America] Strengthen ties with the major IDN/GPO & DoD/VA\* and improve brand awareness and profitability [Rest of World] Comply with laws and regulations related to medical equipment and strengthen local R&D, production, sales, and service capabilities

#### Sales targets by region and product category for FY2026 ending March 2027



<sup>\*</sup> IDN: Integrated Delivery Network, GPO; Group Purchase Organization, DoD: Department of Defense, VA: Veterans Affairs

Quality

# New Three-year Business Plan, BEACON 2030 Phase II

#### **Profitability** Implement the reform of the profit structure • Implement several measures to improve product mix, productivity, and supply chains Area Theme Details of measures FY2026 Target Sale pricing √ Reviewing pricing policies both in Japan and overseas Product Apx. 2% mix Review of product Reviewing and optimizing the number of products lineup ✓ Increasing in-house sales ratio Improving operational efficiency by introducing generative AI: 1.4 Improving personnel productivity, in-√ Focusing on core jobs and reallocating resources: 900 k hours cluding by utilizing generative Al Apx. 2 % Productivity ✓ Reducing the increase of personnel and overtime hours Reducing infrastructure costs such as utility costs, rent Reducing other expenses, and communication expenses, and reviewing traveling expenses √ Refining price negotiations with suppliers **Optimizing parts** Supply Apx. 1 % chain procurement ✓ Promoting Value Analysis/Value Engineering Advance global supply chain management • Enhance PSI (Production, Sales, Inventory) Management, strengthen global QMS (Quality Management System), and promote multi-plant production

### Capital efficiency

#### Introduce Nihon Kohden's own ROIC formula

- Improve profitability and strengthen monitoring of return on investment
  - Manage Nihon Kohden's own ROIC formula in each subsidiary/division, as our business consists of a single segment, medical electronic equipment-related business
  - Measure effectiveness from a mid-to long-term perspective, as R&D costs and personnel expenses in last three years, which are not included B/S, are considered as future investments
  - Figure out ROIC in each subsidiary and promote penetration of NK's ROIC in the Group


# Nihon Kohden's own ROIC calculation formula

### Operating income

#### Invested capital

(future investment\* + accounts receivable + inventory + property, plant and equipment - accounts payable)

\* R&D costs and personnel expenses in last three years



Set cost of capital at 7% conservatively, target of IRR at 12% in Phase II

#### Reduce cash conversion cycle

 Strengthen procurement and production management functions mainly at the newly established Production Operations, Collect debt faster

Three-year Business Plan Phase II target

CCC ~175 days

Cash Conversion Cycle

Mid-term target

CCC ∼150 days